Loading organizations...
PagodaTree Partners operates as a specialized private equity fund manager, primarily focusing its investments on innovations within the healthcare and technology sectors. The firm employs an integrated investment approach, evaluating opportunities for high-growth potential while also considering environmental, social, and governance (ESG) principles across its portfolio companies. This strategic focus positions the firm to support advancements in critical industries through targeted capital deployment.
The firm was established in 2019, emerging from the collective experience of its founding partners who bring significant backgrounds from leading international investment institutions and entrepreneurial ventures. This deep expertise in both finance and industry provides PagodaTree Partners with a nuanced understanding of market dynamics and a robust network for identifying promising opportunities, driving its commitment to supporting emerging innovators.
PagodaTree Partners serves a diverse set of companies seeking capital to fuel their growth and development within the life sciences, healthcare, and advanced technology landscapes. Its long-term vision centers on fostering enterprises that not only deliver strong financial returns but also contribute positively to societal progress, embodying a philosophy of impactful investment.
PagodaTree Partners has 3 tracked investments across 3 companies. The latest tracked deal is $27.8M Series A in Simnova in March 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 11, 2024 | Simnova | $27.8M Series A | — | — |
| Jan 1, 2023 | NextPoint Therapeutics | $80.0M Series B | Juergen Eckhardt, Paulina Hill | Atlas Venture, Polaris Partners, Gordon Freeman, Binney Street Capital, Catalio Capital, Invus, MPM Capital, Sixty Degree Capital |
| May 8, 2020 | Sanbo Brain Hospital | $113.0M Series B | Taikang | CEC Capital |